More on ISIS

- Summary
- Chart
- Profile
- Historical


- Earnings
- Ratings
- Holders


Income Statement
Balance Sheet
Cash Flow Statement


- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks

ISIS Income Statement

Click line-items for a historical chart and %
Research and development revenue under collaborative agreements 41.28M
Licensing and royalty revenue 973K
Total revenue 42.25M
Research and development
General and administrative 4.68M
Total operating expenses 62.11M
Loss from operations -19.86M
Other income (expense):
Equity in net loss of Regulus Therapeutics Inc. 0
Investment income 686K
Interest expense -4.89M
Gain (loss) on investments, net 305K
Loss before income tax expense
Income tax expense
Net loss
Basic net loss (in dollars per share)
Diluted net loss (in dollars per share)
Shares used in computing basic net loss per share (in shares) -215.18M
Shares used in computing diluted net loss per share (in shares) -215.18M